Description: The investment seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive China Biotech Innovation Index (underlying index). The fund invests at least 80% of its total assets, plus borrowings for investments purposes (if any), in the securities of the underlying index and in American Depositary Receipts (ADRs) and Global Depositary Receipts (GDRs) based on the securities in the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are directly involved in China?s biotechnology industry. It is non-diversified.
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
Category: China Region
| Asset Allocation | |||
|---|---|---|---|
| Asset Class | Long % | Short % | Net Assets |
| Stock non-US | 94.80 | 0.00 | 94.80 |
| Stock US | 5.14 | 0.00 | 5.14 |
| Cash | 0.06 | 0.00 | 0.06 |
| Sector Weights | ||
|---|---|---|
| Sector | Equity % | Relative to Category |
| Healthcare | 100.00 | 8.08 |
| World Regions | ||
|---|---|---|
| Region | Equity % | Relative to Category |
| Asia Emerging | 94.86 | 86.05 |
| North America | 5.14 | 0.19 |
| Australasia | 0.00 | 0.04 |
| Latin America | 0.00 | 0.09 |
| Asia Developed | 0.00 | 13.55 |
| United Kingdom | 0.00 | 0.06 |
| Europe Developed | 0.00 | 0.02 |